import React from 'react';
import Link from 'next/link';
import AdBlock from '@/components/AdBlock';

export default function CompleteGuideGLP1WeightLossPage() {
  return (
    <div className="max-w-4xl mx-auto">
      <div className="mb-8">
        <span className="inline-block bg-accent/10 text-accent text-sm px-3 py-1 rounded-full">
          GLP-1 &amp; Weight Loss
        </span>
        <h1 className="text-3xl md:text-4xl font-bold mt-2 mb-4">
          GLP-1 Medications for Weight Loss: What the Research Actually Shows
        </h1>
        <p className="text-gray-500 italic">Published: January 5, 2026 &bull; 18 min read</p>
      </div>

      <div className="prose prose-lg max-w-none">
        <div className="neumorph p-6 rounded-lg mb-8">
          <h2 className="text-xl font-semibold mb-4">Key Takeaways</h2>
          <ul className="space-y-2">
            <li>
              GLP-1 receptor agonists work by mimicking a gut hormone that signals fullness to your
              brain, slowing gastric emptying, and reducing appetite at a neurological level
            </li>
            <li>
              Semaglutide (Wegovy) produces average weight loss of about 15% of body weight over 68
              weeks. Tirzepatide (Zepbound) averages 20-22% in the same timeframe.
            </li>
            <li>
              Weight regain is real: the STEP 1 extension trial showed participants regained roughly
              two-thirds of lost weight within one year of stopping the medication
            </li>
            <li>
              Monthly costs without insurance range from $900 to $1,350, though manufacturer
              discount programs and compounding pharmacies have changed the pricing picture
            </li>
            <li>
              These medications work best when combined with a high-protein diet and resistance
              training to preserve lean muscle mass
            </li>
          </ul>
        </div>

        <p>
          I want to be upfront about something. GLP-1 medications are the most significant
          development in obesity treatment in decades. They are also wildly overhyped, poorly
          understood by most people taking them, and surrounded by misinformation from every
          direction. Pharma companies oversell the benefits. Social media undersells the risks. And
          most coverage glosses over the single biggest question: what happens when you stop?
        </p>

        <p>
          This guide is my attempt to lay out what the clinical data actually shows. Not the
          marketing. Not the TikTok testimonials. The research.
        </p>

        <AdBlock format="horizontal" />

        <h2 className="text-2xl font-bold mt-10 mb-4">What GLP-1 Receptor Agonists Actually Are</h2>

        <p>
          GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut naturally produces
          after you eat. When food hits your small intestine, specialized L-cells release GLP-1 into
          your bloodstream. That GLP-1 does several things at once.
        </p>

        <p>
          First, it tells your pancreas to release insulin. This is why GLP-1 drugs were originally
          developed for type 2 diabetes. Second, it slows gastric emptying, meaning food sits in
          your stomach longer. You feel full faster and stay full longer. Third, and this is the
          part that matters most for weight loss, it acts on receptors in the hypothalamus and
          brainstem to reduce appetite.
        </p>

        <p>
          Natural GLP-1 breaks down in your body within about 2 minutes. The pharmaceutical versions
          are engineered to last much longer. Semaglutide has a half-life of roughly 7 days, which
          is why it works as a weekly injection. The drug attaches to albumin in your blood, which
          shields it from the enzymes that would normally chew it up.
        </p>

        <p>
          Tirzepatide goes a step further. It is a dual agonist, hitting both the GLP-1 receptor and
          the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut
          hormone involved in satiety. By targeting both pathways, tirzepatide produces stronger
          appetite suppression and greater weight loss in clinical trials.
        </p>

        <p>
          This is not a willpower drug. It is changing the hormonal signaling in your brain. People
          on these medications consistently report that "food noise," the constant background
          chatter about what to eat next, goes quiet. That is a neurological effect, not a
          psychological one.
        </p>

        <div className="neumorph-card rounded-xl p-6 my-8 bg-blue-50 dark:bg-blue-900/20">
          <h3 className="text-xl font-semibold mb-3 text-gray-900 dark:text-white">
            Estimate Your Targets
          </h3>
          <p className="text-gray-700 dark:text-gray-300 mb-4">
            If you are taking or considering a GLP-1 medication, our calculator can give you
            personalized calorie and protein targets based on your medication, body stats, and
            activity level.
          </p>
          <div className="flex flex-wrap gap-3">
            <Link
              href="/glp1-calculator"
              className="neumorph-button px-4 py-2 rounded-lg text-sm font-medium hover:scale-105 transition-transform"
            >
              GLP-1 Nutrition Calculator
            </Link>
          </div>
        </div>

        <h2 className="text-2xl font-bold mt-10 mb-4">
          The Clinical Trial Data: What the Numbers Say
        </h2>

        <h3 className="text-xl font-semibold mt-8 mb-3">Semaglutide: The STEP Trial Program</h3>

        <p>
          The STEP (Semaglutide Treatment Effect in People with Obesity) trials are the foundation
          of everything we know about semaglutide for weight loss. STEP 1 was the big one. Published
          in the New England Journal of Medicine in 2021, it enrolled 1,961 adults with a BMI of 30
          or higher (or 27+ with at least one weight-related condition). None had diabetes.
        </p>

        <p>
          Participants received either weekly semaglutide 2.4 mg or placebo, plus lifestyle
          counseling. After 68 weeks, the semaglutide group lost an average of 14.9% of their body
          weight, compared to 2.4% in the placebo group. For a 220-pound person, that is about 33
          pounds versus 5 pounds.
        </p>

        <p>
          But averages hide a lot of variation. Roughly one-third of participants lost more than 20%
          of their body weight. About 10% lost less than 5%. Individual response varies enormously,
          and nobody fully understands why yet.
        </p>

        <p>
          STEP 2 looked at semaglutide in people with type 2 diabetes. Weight loss was lower (about
          9.6% at 68 weeks), which tells us something important: diabetes changes the metabolic
          equation. People with insulin resistance tend to lose less weight on these medications.
        </p>

        <p>
          STEP 3 combined semaglutide with intensive behavioral therapy (meal replacements, exercise
          coaching, 30 counseling sessions). Weight loss was 16%, slightly better than medication
          alone. The takeaway: the drug does most of the heavy lifting, but lifestyle intervention
          adds a real but modest benefit.
        </p>

        <p>
          STEP 5 extended the treatment to 104 weeks (2 years). Average weight loss was 15.2%, and
          it was largely sustained for the duration of treatment. This matters because it shows the
          medication keeps working as long as you keep taking it.
        </p>

        <h3 className="text-xl font-semibold mt-8 mb-3">Tirzepatide: The SURMOUNT Trial Program</h3>

        <p>
          The SURMOUNT trials tested tirzepatide (Eli Lilly's dual GLP-1/GIP agonist) for weight
          loss. SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539
          adults without diabetes.
        </p>

        <p>
          The results were genuinely striking. At the highest dose (15 mg), participants lost an
          average of 22.5% of their body weight over 72 weeks. At the middle dose (10 mg), it was
          21.4%. At the lowest dose (5 mg), 15%.
        </p>

        <p>
          To put those numbers in context: bariatric surgery, which is the most effective weight
          loss intervention we have, typically produces 25-30% weight loss. Tirzepatide at the
          highest dose is getting within striking distance of surgical results without surgery.
        </p>

        <p>
          SURMOUNT-2 looked at tirzepatide in people with type 2 diabetes and found 12.8% to 14.7%
          weight loss, again confirming that diabetes blunts the weight loss effect somewhat.
        </p>

        <div className="overflow-x-auto my-8">
          <table className="min-w-full text-sm border border-gray-200 dark:border-gray-700">
            <thead>
              <tr className="bg-gray-50 dark:bg-gray-800">
                <th className="px-4 py-3 text-left font-semibold">Trial</th>
                <th className="px-4 py-3 text-left font-semibold">Drug</th>
                <th className="px-4 py-3 text-left font-semibold">Population</th>
                <th className="px-4 py-3 text-left font-semibold">Duration</th>
                <th className="px-4 py-3 text-left font-semibold">Avg Weight Loss</th>
              </tr>
            </thead>
            <tbody className="divide-y divide-gray-200 dark:divide-gray-700">
              <tr>
                <td className="px-4 py-3">STEP 1</td>
                <td className="px-4 py-3">Semaglutide 2.4 mg</td>
                <td className="px-4 py-3">Non-diabetic, BMI 30+</td>
                <td className="px-4 py-3">68 weeks</td>
                <td className="px-4 py-3 font-semibold">14.9%</td>
              </tr>
              <tr>
                <td className="px-4 py-3">STEP 2</td>
                <td className="px-4 py-3">Semaglutide 2.4 mg</td>
                <td className="px-4 py-3">Type 2 diabetes, BMI 27+</td>
                <td className="px-4 py-3">68 weeks</td>
                <td className="px-4 py-3 font-semibold">9.6%</td>
              </tr>
              <tr>
                <td className="px-4 py-3">STEP 3</td>
                <td className="px-4 py-3">Semaglutide 2.4 mg + IBT</td>
                <td className="px-4 py-3">Non-diabetic, BMI 30+</td>
                <td className="px-4 py-3">68 weeks</td>
                <td className="px-4 py-3 font-semibold">16.0%</td>
              </tr>
              <tr>
                <td className="px-4 py-3">STEP 5</td>
                <td className="px-4 py-3">Semaglutide 2.4 mg</td>
                <td className="px-4 py-3">Non-diabetic, BMI 30+</td>
                <td className="px-4 py-3">104 weeks</td>
                <td className="px-4 py-3 font-semibold">15.2%</td>
              </tr>
              <tr>
                <td className="px-4 py-3">SURMOUNT-1</td>
                <td className="px-4 py-3">Tirzepatide 15 mg</td>
                <td className="px-4 py-3">Non-diabetic, BMI 30+</td>
                <td className="px-4 py-3">72 weeks</td>
                <td className="px-4 py-3 font-semibold">22.5%</td>
              </tr>
              <tr>
                <td className="px-4 py-3">SURMOUNT-1</td>
                <td className="px-4 py-3">Tirzepatide 10 mg</td>
                <td className="px-4 py-3">Non-diabetic, BMI 30+</td>
                <td className="px-4 py-3">72 weeks</td>
                <td className="px-4 py-3 font-semibold">21.4%</td>
              </tr>
              <tr>
                <td className="px-4 py-3">SURMOUNT-2</td>
                <td className="px-4 py-3">Tirzepatide 15 mg</td>
                <td className="px-4 py-3">Type 2 diabetes, BMI 27+</td>
                <td className="px-4 py-3">72 weeks</td>
                <td className="px-4 py-3 font-semibold">14.7%</td>
              </tr>
            </tbody>
          </table>
        </div>

        <AdBlock format="horizontal" />

        <h2 className="text-2xl font-bold mt-10 mb-4">Who Responds Best (and Who Doesn&apos;t)</h2>

        <p>
          Not everyone loses the same amount. Post-hoc analyses from the STEP trials have identified
          some patterns worth knowing about.
        </p>

        <p>
          People without type 2 diabetes tend to lose more weight. This is consistent across every
          major trial. Younger participants generally respond better than older ones, though the
          difference is modest. Women tend to lose a slightly higher percentage of body weight than
          men, possibly because women start with higher body fat percentages.
        </p>

        <p>
          Higher starting BMI does not necessarily predict greater percentage weight loss, which
          surprises a lot of people. Someone with a BMI of 32 might lose 18% of their body weight
          while someone with a BMI of 45 loses 12%. The absolute pounds lost may be higher at higher
          weights, but the percentage can go either way.
        </p>

        <p>
          One strong predictor: early response. A 2023 analysis published in Lancet Diabetes &amp;
          Endocrinology found that weight loss at 12 weeks was a reliable predictor of weight loss
          at 68 weeks. If you have lost at least 5% of your body weight by week 12, you are likely
          to be a strong responder. If you have lost less than 2%, your long-term results are likely
          to be modest.
        </p>

        <p>
          This matters for practical decision-making. If after 3 months at a therapeutic dose you
          are seeing minimal results, it may be worth discussing alternatives with your doctor
          rather than assuming the drug just needs more time.
        </p>

        <h2 className="text-2xl font-bold mt-10 mb-4">
          The Weight Regain Problem Nobody Wants to Talk About
        </h2>

        <p>Here is where the conversation gets uncomfortable.</p>

        <p>
          The STEP 1 trial extension study, published in the journal Diabetes, Obesity and
          Metabolism in 2022, followed participants for one year after they stopped taking
          semaglutide. The results were sobering. Participants regained approximately two-thirds of
          the weight they had lost within 52 weeks of discontinuation. They also lost the
          cardiometabolic improvements they had achieved (improvements in blood pressure, blood
          sugar, and lipids partially reversed).
        </p>

        <p>
          SURMOUNT-4 showed a nearly identical pattern with tirzepatide. Participants who switched
          from tirzepatide to placebo regained about half their lost weight in 52 weeks, and the
          trajectory suggested further regain would continue.
        </p>

        <p>
          This is not a failure of the medication. It is biology. Obesity, for most people, is a
          chronic condition driven by hormonal and neurological factors that the medication
          corrects. When you remove the medication, those factors reassert themselves. The same way
          blood pressure rises again when you stop taking blood pressure medication.
        </p>

        <p>
          The implication is clear: for most people, GLP-1 medications work best as a long-term
          treatment, not a short course. That has enormous implications for cost, access, and how we
          think about these drugs.
        </p>

        <p>
          Some researchers are exploring whether lower maintenance doses might prevent full regain.
          A 2024 Obesity study examined using half-doses after initial weight loss was achieved and
          found partial maintenance of weight loss, but the data is still preliminary.
        </p>

        <div className="neumorph-card rounded-xl p-6 my-8 bg-yellow-50 dark:bg-yellow-900/20">
          <h3 className="text-xl font-semibold mb-3 text-gray-900 dark:text-white">
            Plan for the Long Term
          </h3>
          <p className="text-gray-700 dark:text-gray-300 mb-4">
            If you are starting a GLP-1 medication, building sustainable nutrition habits from the
            beginning is critical. Our{' '}
            <Link
              href="/glp1-calculator"
              className="text-blue-600 dark:text-blue-400 hover:underline"
            >
              GLP-1 calculator
            </Link>{' '}
            helps you set protein and calorie targets that support muscle preservation, which is one
            of the most important factors in long-term weight maintenance.
          </p>
        </div>

        <h2 className="text-2xl font-bold mt-10 mb-4">The Muscle Loss Problem</h2>

        <p>
          When you lose weight rapidly, you do not just lose fat. You lose muscle too. This is true
          regardless of how you lose the weight, but GLP-1 medications create a specific challenge:
          they suppress appetite so aggressively that many people struggle to eat enough protein.
        </p>

        <p>
          Data from the STEP trials showed that about 25-40% of total weight lost was lean body mass
          rather than fat. That is a higher ratio than what you would expect from a well-managed
          diet with adequate protein and resistance training.
        </p>

        <p>
          Why does this matter? Muscle mass is your metabolic engine. It determines how many
          calories you burn at rest, it protects your joints, it keeps you functional as you age.
          Losing 30 pounds of fat and 15 pounds of muscle leaves you lighter but metabolically worse
          off than losing 40 pounds of fat and 5 pounds of muscle.
        </p>

        <p>
          The fix is straightforward in theory: eat enough protein (at least 1.2 grams per kilogram
          of body weight, ideally 1.6-2.0 g/kg) and do resistance training at least twice a week. In
          practice, when nausea is making it hard to eat a full meal, hitting 120+ grams of protein
          daily feels like a second job.
        </p>

        <p>
          Prioritize protein at every meal. Eat your protein first before anything else on the
          plate. Consider protein supplements if whole food is not realistic. This is not optional
          advice if you want to come out of GLP-1 treatment in good shape.
        </p>

        <h2 className="text-2xl font-bold mt-10 mb-4">Who Should Consider GLP-1 Medications</h2>

        <p>
          The FDA-approved criteria for Wegovy (semaglutide for weight loss) are: BMI of 30 or
          greater, or BMI of 27 or greater with at least one weight-related comorbidity (type 2
          diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea).
        </p>

        <p>
          In my view, the people who benefit most are those who have genuinely tried lifestyle
          changes and hit a biological wall. Someone who has been eating well and exercising
          consistently for years but cannot get their weight below a certain threshold due to
          hormonal factors. Someone whose hunger signals are genuinely dysregulated, not someone who
          skips breakfast and eats fast food and has never seriously tried.
        </p>

        <p>
          I know that last sentence will be controversial. But these drugs have real side effects,
          cost a fortune, and may need to be taken indefinitely. Starting them before exhausting
          simpler approaches does not make sense to me.
        </p>

        <h3 className="text-xl font-semibold mt-8 mb-3">Who Should Not Take GLP-1 Medications</h3>

        <ul className="space-y-2 mb-6">
          <li>
            <strong>Personal or family history of medullary thyroid carcinoma (MTC).</strong> This
            is an absolute contraindication. Semaglutide and tirzepatide caused thyroid C-cell
            tumors in rodent studies. More on what this means for humans below.
          </li>
          <li>
            <strong>
              Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
            </strong>{' '}
            Same thyroid concern.
          </li>
          <li>
            <strong>History of pancreatitis.</strong> GLP-1 medications can increase the risk of
            pancreatitis, so a prior history is a relative contraindication.
          </li>
          <li>
            <strong>Pregnancy or planning pregnancy.</strong> These medications should be stopped at
            least 2 months before trying to conceive, given semaglutide&apos;s long half-life.
          </li>
          <li>
            <strong>Severe gastroparesis.</strong> Since GLP-1s slow gastric emptying, they can
            worsen pre-existing motility disorders.
          </li>
          <li>
            <strong>Active eating disorders.</strong> The appetite suppression can mask and worsen
            disordered eating patterns. This one does not get discussed enough.
          </li>
        </ul>

        <AdBlock format="horizontal" />

        <h2 className="text-2xl font-bold mt-10 mb-4">The Cost Reality</h2>

        <p>
          Let&apos;s talk money, because this is where the rubber meets the road for most people.
        </p>

        <div className="overflow-x-auto my-8">
          <table className="min-w-full text-sm border border-gray-200 dark:border-gray-700">
            <thead>
              <tr className="bg-gray-50 dark:bg-gray-800">
                <th className="px-4 py-3 text-left font-semibold">Medication</th>
                <th className="px-4 py-3 text-left font-semibold">List Price/Month</th>
                <th className="px-4 py-3 text-left font-semibold">With Manufacturer Savings</th>
                <th className="px-4 py-3 text-left font-semibold">With Good Insurance</th>
              </tr>
            </thead>
            <tbody className="divide-y divide-gray-200 dark:divide-gray-700">
              <tr>
                <td className="px-4 py-3">Wegovy (semaglutide)</td>
                <td className="px-4 py-3">~$1,350/month</td>
                <td className="px-4 py-3">Varies, often $0-$500</td>
                <td className="px-4 py-3">$25-$150 copay</td>
              </tr>
              <tr>
                <td className="px-4 py-3">Zepbound (tirzepatide)</td>
                <td className="px-4 py-3">~$1,060/month</td>
                <td className="px-4 py-3">$550 savings card available</td>
                <td className="px-4 py-3">$25-$150 copay</td>
              </tr>
              <tr>
                <td className="px-4 py-3">Ozempic (semaglutide, off-label)</td>
                <td className="px-4 py-3">~$935/month</td>
                <td className="px-4 py-3">Diabetes savings programs</td>
                <td className="px-4 py-3">$25-$100 copay</td>
              </tr>
              <tr>
                <td className="px-4 py-3">Compounded semaglutide</td>
                <td className="px-4 py-3">$200-$500/month</td>
                <td className="px-4 py-3">N/A</td>
                <td className="px-4 py-3">Not covered</td>
              </tr>
            </tbody>
          </table>
        </div>

        <p>
          Insurance coverage is wildly inconsistent. Medicare does not cover weight loss medications
          (though legislation to change this has been introduced). Many private insurers cover
          Wegovy or Zepbound but require prior authorization and evidence of failed lifestyle
          interventions. Some employers explicitly exclude obesity medications from their plans.
        </p>

        <p>
          The compounded semaglutide market exploded in 2023-2024 while brand-name drugs were in
          shortage. Compounding pharmacies were legally allowed to produce semaglutide because the
          FDA had listed it as "in shortage." As shortages resolve, the FDA has moved to restrict
          compounding, creating a gray area. Compounded versions are cheaper but come with questions
          about quality control, dosing accuracy, and legal status that change month to month.
        </p>

        <p>
          If you are paying out of pocket, you are looking at a minimum of $10,000-$16,000 per year
          for brand-name medications. That is a significant financial commitment, especially for a
          drug you may need to take indefinitely.
        </p>

        <h2 className="text-2xl font-bold mt-10 mb-4">
          Beyond Weight: Other Benefits the Trials Found
        </h2>

        <p>
          The weight loss gets all the headlines. But the metabolic improvements may matter more in
          the long run.
        </p>

        <p>
          The SELECT trial, published in the New England Journal of Medicine in 2023, studied
          semaglutide specifically for cardiovascular outcomes in overweight and obese adults
          without diabetes but with established cardiovascular disease. Participants taking
          semaglutide had a 20% reduction in major adverse cardiovascular events (heart attack,
          stroke, or cardiovascular death) compared to placebo.
        </p>

        <p>
          That is a massive finding. For context, statins, which are considered one of the most
          important medications in cardiovascular prevention, typically reduce cardiovascular events
          by about 25-30%. Semaglutide is approaching similar territory.
        </p>

        <p>
          Other documented benefits from the clinical trial data include: reduction in hemoglobin
          A1c (even in non-diabetic patients), improvements in blood pressure (average reduction of
          4-6 mmHg systolic), improvements in triglycerides and HDL cholesterol, reduced markers of
          systemic inflammation (C-reactive protein dropped significantly), and improvements in
          liver fat content (relevant for people with fatty liver disease).
        </p>

        <p>
          Research on kidney outcomes, sleep apnea, and heart failure is ongoing. Early results from
          the FLOW trial showed a 24% reduction in kidney disease progression with semaglutide, and
          the trial was actually stopped early because the benefit was so clear.
        </p>

        <h2 className="text-2xl font-bold mt-10 mb-4">Making It Work: Practical Recommendations</h2>

        <p>
          Based on my reading of the literature and talking to clinicians who prescribe these drugs
          daily, here is what actually matters for getting the best results.
        </p>

        <p>
          <strong>Protein first, always.</strong> Aim for 1.2 to 2.0 grams per kilogram of body
          weight daily. At every meal, eat your protein source before anything else. When your
          appetite is suppressed and you can only eat 1,200 calories, those calories need to be
          mostly protein. Use our{' '}
          <Link
            href="/glp1-calculator"
            className="text-blue-600 dark:text-blue-400 hover:underline"
          >
            GLP-1 nutrition calculator
          </Link>{' '}
          to get personalized targets based on your specific medication and goals.
        </p>

        <p>
          <strong>Resistance train consistently.</strong> Two to three sessions per week. Compound
          movements: squats, deadlifts, rows, presses. This is the single most important thing you
          can do to preserve muscle mass while losing weight on GLP-1s.
        </p>

        <p>
          <strong>Hydrate aggressively.</strong> Many GLP-1 side effects (nausea, constipation,
          headaches) are worsened by dehydration. Aim for at least 2 liters of water daily. More if
          you are exercising.
        </p>

        <p>
          <strong>Titrate slowly.</strong> Every GLP-1 medication has a dose escalation schedule for
          a reason. Rushing to the highest dose increases side effects without meaningfully
          accelerating weight loss. If your provider wants to jump you straight to a maintenance
          dose, push back.
        </p>

        <p>
          <strong>Track your progress beyond the scale.</strong> Body measurements, progress photos,
          how your clothes fit, energy levels, blood work. The scale number alone tells you almost
          nothing about whether you are losing fat versus muscle.
        </p>

        <h2 className="text-2xl font-bold mt-10 mb-4">The Bottom Line</h2>

        <p>
          GLP-1 medications are a genuine breakthrough. They produce weight loss that was previously
          only achievable through surgery. They improve cardiovascular outcomes, metabolic markers,
          and quality of life.
        </p>

        <p>
          They are also expensive, require long-term use, cause significant side effects in many
          people, and do not replace the need for good nutrition and exercise. They are a tool, not
          a solution. The best outcomes come from treating them as the foundation of a plan that
          includes adequate protein, resistance training, and realistic expectations about what
          happens when (or if) you stop.
        </p>

        <p>
          If you are considering a GLP-1 medication, have an honest conversation with your doctor
          about your specific situation. Use our{' '}
          <Link
            href="/glp1-calculator"
            className="text-blue-600 dark:text-blue-400 hover:underline"
          >
            GLP-1 calculator
          </Link>{' '}
          to understand what your nutritional needs will look like on treatment. And go in with your
          eyes open about both the benefits and the limitations.
        </p>

        <p>
          The research is clear on one thing: these medications work. How well they work for you
          depends on everything you do around them.
        </p>

        <div className="neumorph p-6 rounded-lg mt-8">
          <h2 className="text-xl font-semibold mb-4">Sources</h2>
          <ul className="space-y-1 text-sm text-gray-600 dark:text-gray-400">
            <li>
              Wilding JPH, et al. &quot;Once-Weekly Semaglutide in Adults with Overweight or
              Obesity.&quot; NEJM, 2021. (STEP 1)
            </li>
            <li>
              Davies M, et al. &quot;Semaglutide 2.4 mg once a week in adults with overweight or
              obesity, and type 2 diabetes.&quot; Lancet, 2021. (STEP 2)
            </li>
            <li>
              Wadden TA, et al. &quot;Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to
              Intensive Behavioral Therapy on Body Weight.&quot; JAMA, 2021. (STEP 3)
            </li>
            <li>
              Garvey WT, et al. &quot;Two-year effects of semaglutide in adults with overweight or
              obesity.&quot; Nature Medicine, 2022. (STEP 5)
            </li>
            <li>
              Jastreboff AM, et al. &quot;Tirzepatide Once Weekly for the Treatment of
              Obesity.&quot; NEJM, 2022. (SURMOUNT-1)
            </li>
            <li>
              Garvey WT, et al. &quot;Tirzepatide Once Weekly for the Treatment of Obesity in People
              with Type 2 Diabetes.&quot; NEJM, 2023. (SURMOUNT-2)
            </li>
            <li>
              Wilding JPH, et al. &quot;Weight regain and cardiometabolic effects after withdrawal
              of semaglutide.&quot; Diabetes, Obesity and Metabolism, 2022. (STEP 1 extension)
            </li>
            <li>
              Lincoff AM, et al. &quot;Semaglutide and Cardiovascular Outcomes in Obesity without
              Diabetes.&quot; NEJM, 2023. (SELECT)
            </li>
            <li>
              Perkovic V, et al. &quot;Effects of Semaglutide on Chronic Kidney Disease in Patients
              with Type 2 Diabetes.&quot; NEJM, 2024. (FLOW)
            </li>
          </ul>
        </div>
      </div>
    </div>
  );
}
